TY - JOUR
TI - Serum Dickkopf-1 is increased and correlates with reduced bone mineral
density in patients with thalassemia-induced osteoporosis. Reduction
post-zoledronic acid administration
AU - Voskaridou, Ersi
AU - Christoulas, Dimitrios
AU - Xirakia, Charoula and
AU - Varvagiannis, Konstantinos
AU - Boutsikas, Georgios
AU - Bilalis, Antonios
AU - and Kastritis, Efstathios
AU - Papatheodorou, Athanasios
AU - Terpos,
AU - Evangelos
JO - Haematologica-the hematology journal
PY - 2009
VL - 94
TODO - 5
SP - 725-728
PB - Ferrata Storti Foundation
SN - null
TODO - 10.3324/haematol.2008.000893
TODO - thalassemia; osteoporosis; Dickkopf-1; osteoblast; zoledronic acid
TODO - Dickkopf-1 is an inhibitor of Wnt signaling, which is crucial for
osteoblast differentiation. We evaluated serum levels of Dickkopf-1 in
66 patients with thalassemia-induced osteoporosis who received therapy
with zoledronic acid in a placebo-controlled, randomized trial. At
baseline, thalassemia patients had increased serum levels of Dickkopf-1
that correlated with reduced bone mineral density of the lumbar spine
and the distal radius. High Dickkopf-1 also correlated with increased
bone resorption and reduced bone formation markets. Zoledronic acid
produced a reduction in serum Dickkopf-1, which was associated with bone
mineral density increase after 12 months of therapy. On the contrary,
placebo group showed a borderline increase of Dickkopf-1, which was
higher in patients who showed deterioration in pain scores. These
results suggest that Dickkopf-1 is implicated in the pathogenesis of
osteoporosis in thalassemia and reveal Dickkopf-1 as a possible target
for the development of novel agents for the management of
thalassemia-induced osteoporosis (ClinicalTrials. got., Identifier:
NCT00346242).
ER -